Review article · 2020
Short communicationPublished 21 May 2022
Spinal Muscular Atrophy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Spinal Muscular Atrophy (SMA) is a very severe neurodegenerative disease which causes progressive muscle atrophy and weakness due to loss of the anterior horn cells in the spinal cord and the lower brain stem nuclei. SMA is second most common autosomal recessive disorder and the most common genetic cause of death in infancy. It is caused bydeficiency of survival of motor neuron (SMN) protein due to pathogenic variant in the SMN1 gene. SMA is classified clinically into four subtypes based on the age of onset and maximum motor function achieved. SMA type 1 (most severe form) is present with weakness and hypotonia before six months of age. Type II manifest between ages six and 12 months. Type III manifests between ages 18 to 36 months.Type IV (adult onset) develops muscle weakness in second or third decade. There is no cure for SMA and until recently only supportive treatment was available but the approval of Nusinersen and Zolgesma, has revolutionized the outcome of SMA. Nusinersen (Spinraza) is an antisense oligonucleotide forthe treatment of SMA that increases the production of full length SMN protein. Zolgesma is a gene therapy that restores the deleted SMN1 gene. Both Nusinersen and Zolgesma have demonstrated significant and clinically meaningful efficacy on the achievement of motor milestones and measures of motor function, as well as favorable safety across all types of SMA and significantly greater event free survival in infants with infantile-onset SMA. It’s important to recognize some of the early signs and symptoms of SMA and diagnose presymptomatic patients by Newborn screen for better outcome of this devastating disease.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2020
Spinal Muscular Atrophy- Emerging therapies and future directions
Conference abstract · 18 Mar 2019
Assessment of awareness of the early clinical features of Spinal Muscular Atrophy (SMA) amongst pediatricians
Mini review · 24 May 2024
Advancements in the Treatment of Pediatric Spinal Muscular Atrophy
Commentary · 1 Jul 2026
Precision Splice-Modulating Antisense Oligonucleotide Strategy for Spinal Muscular Atrophy Type II Functional Recovery Assessment
More from this journal
The newest in Pediatric Infectious Diseases: Open Access.
Commentary · 7 Feb 2025
Antimicrobial Resistance in Pediatric Respiratory Infections: A Decade of Change
Brief report · 7 Feb 2025
Emerging Viral Pathogens in Pediatric Populations: Trends and Global Health Implications
Short communication · 4 Feb 2025
Nosocomial Infections in Pediatric Intensive Care Units: A Ten-Year Retrospective Study
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPediatric Infectious Diseases: Open Access
- SubjectInfectious Diseases
- SubjectPaediatrics & Neonatology
- BylineArticles whose byline prints “Farida Abid”

